FALCO HOLDINGS Co., Ltd.
4671・Standard Market・Services
Clinical Laboratory Testing Business
Core business accounting for approximately 61% of Group sales. Centers on Contract Clinical Specimen Testing while also developing the genome business.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales | ¥26,662 million | ¥26,397 million | ↑ |
| Operating Income | ¥1,816 million | ¥1,594 million | ↑ |
| Segment Assets | ¥9,302 million | ¥9,463 million | ↓ |
| Depreciation and Amortization | ¥575 million | ¥513 million | ↑ |
| Capital Expenditures (increase in tangible/intangible fixed assets) | ¥728 million | ¥624 million | ↑ |
Business Details
Accepts contract clinical specimen testing from hospitals and clinics nationwide and provides test results. Also engages in the manufacture and sale of in-vitro diagnostic pharmaceuticals. The business promotes expansion focused on major metropolitan areas and pursues cost structure improvement through strengthened specimen collection systems and testing operation efficiency via IT utilization. The genome business (NIPT, MSI Test Kit, Hereditary Tumor Panel Testing) is also positioned as a growth area, with a strategy to capture the advancement of personalized medicine.
Recent Overview
Net sales increased 1.0% and operating income increased 13.9% due to increased contracted test volume and cost improvements, significantly improving profitability.
In the Clinical Laboratory Testing Business for FY2026 (ending March 2026), net sales reached ¥26,662 million (up 1.0% year on year) and operating income reached ¥1,816 million (up 13.9% year on year). In addition to increased contracted test volume driven by expansion focused on major metropolitan areas, strengthened specimen collection systems and improved testing operation efficiency through IT promotion contributed to productivity gains and cost structure improvement. In the genome business, NIPT saw increased contracted test volume and expanded sales channels, while the MSI Test Kit also performed steadily. Research and development for Hereditary Tumor Panel Testing continues toward regulatory application and insurance coverage.
Key Products
Growth Drivers
- Increased contracted test volume through business development focused on major metropolitan areas
- Cost structure improvement and productivity gains through strengthened specimen collection systems and enhanced testing operation efficiency via IT promotion
- Steady sales performance of the in-vitro diagnostic pharmaceutical "MSI Test Kit (FALCO)"
- Increased contracted test volume and expanded sales channels for genetic testing related to perinatal medicine (NIPT)
- Future market expansion through research and development toward regulatory application and insurance coverage for Hereditary Tumor Panel Testing
- Increasing importance of genetic testing in genomic medicine and growing expectations for personalized medicine
Risks
- Downward pressure on contracted testing unit prices due to continued healthcare cost containment policies
- Cost increases (testing reagents, labor costs, etc.) driven by rising prices and wages
- Changes in the number of medical institutions and consultation trends amid declining birthrate and aging population
- Risk of delays in regulatory application and insurance coverage for the genome business
- Risk of declining profitability due to intensifying price competition with competitors
- Risk of increased costs due to rising material prices driven by factors such as Middle East tensions
Last updated: June 24, 2026